Related Experiment Videos
US Food and Drug Administration Facilitated Pediatric Approval Programs: Application to Pediatric Neurological
Emily Da Cruz1, Faraan Rahim1, Monica Lemmon1
1Division of Pediatric Neurology and Developmental Medicine, Department of Pediatrics, Duke University, Durham, NC, USA.
Insights
Pediatric drug development faces hurdles, but FDA programs can accelerate new therapies for neurological disorders. Incentives are crucial for improving treatment access for these vulnerable patients.
Area of Science:
- Neurology
- Pediatric Medicine
- Pharmacology
Background:
- Pediatric neurological disorders often manifest aggressively, leading to devastating effects.
- Significant logistical, ethical, and financial barriers impede pediatric drug development studies.
- Timely access to effective therapies is critical for children with neurological conditions.
Purpose of the Study:
- To review Food and Drug Administration (FDA) programs that facilitate pediatric drug development.
- To focus on the application of these programs to pediatric neurological disorders.
- To highlight ethical considerations and the need for incentives in pediatric drug development.
Main Methods:
- Review of FDA programs designed for pediatric drug development.
- Analysis of drugs that have utilized or are utilizing these FDA programs for pediatric neurological disorders.
- Examination of commonalities among drugs receiving expedited development designations.
Main Results:
- FDA programs offer pathways to expedite the development of drugs for pediatric neurological conditions.
- Examples of drugs that have benefited from or are part of these FDA initiatives are provided.
- Identification of ethical issues and the necessity for structured incentives in pediatric drug development.
Conclusions:
- Streamlining drug approval processes through FDA programs can improve access to treatments for pediatric neurological disorders.
- Addressing ethical concerns and implementing structured incentives are vital for advancing pediatric neurology drug development.
- Consolidated information on drug approval for pediatric neurological disorders can aid stakeholders in enhancing treatment development.
Abstract:
Crucial time is often lost while waiting for approval of therapies for pediatric neurological disorders, many of which have aggressive manifestations with devastating effects. There are logistical, ethical, and financial impediments that face the studies needed to determine efficacy and safety of therapies in children. In this article, the authors present the Food and Drug Administration's programs aimed at facilitating the development of pediatric drugs, focusing on their application to pediatric neurological disorders. They also provide examples of drugs that received, or are currently enrolled in, these programs. Reflecting upon the commonalities of drugs receiving these designations, the authors highlight underlying ethical issues related to pediatric drug development and emphasize the need for structured incentives to stimulate approval and production of drug therapies for pediatric neurology patients. By consolidating information that applies to drug approval of pediatric neurological disorders, stakeholders in drug development can enhance treatment development for these disorders.